X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

By Juliet Johnson  |    September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines.  These...   Read More

How much do you know about Medicare Part B?

By Nicole Longo  |    July 31, 2018
In recent months, the Administration has proposed a number of changes to Medicare Part B. From the Department of Health and Human Services’ request for information, HHS Blueprint To Lower Drug...   Read More

How ICER’s assessment of a new class of migraine treatments fails patients

By Lauren Neves  |    July 10, 2018
Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their...   Read More

New report shows over 500 medicines in development for neurological disorders

By Andrew Powaleny  |    April 18, 2018
Neurological disorders, which include more than 1,000 conditions that disrupt the brain and nervous system, affect an estimated 100 million Americans, nearly one third of the U.S. population....   Read More

Fact Check Friday: The truth about the cost of 340B to patients

By Nicole Longo  |    January 26, 2018
The 340B program was designed to increase access to medicines for vulnerable or uninsured patients through safety-net facilities, but all signs point to 340B doing the opposite – distorting the...   Read More

340B Spotlight: New pieces of legislation continue momentum to fix 340B program

By Nicole Longo  |    January 18, 2018
In case you missed it, two new pieces of legislation have been introduced to increase oversight of and fix the 340B program. Before the holidays, Representatives Larry Bucshon and Scott Peters...   Read More

340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform

By Nicole Longo  |    October 20, 2017
Evidence that the 340B program has strayed from its congressionally stated intent – and is now benefiting wealthy hospitals instead of patients – has been piling up, and members of Congress have...   Read More

VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria

By Holly Campbell  |    October 12, 2017
PhRMA president and CEO Stephen J. Ubl joined Fox Business’ Maria Bartiromo on “Mornings with Maria” today to discuss bold steps the biopharmaceutical industry has taken in the last few months as...   Read More

Medicare Monday: A discussion on affordability and access to medicines

By Nicole Longo  |    March 27, 2017
In case you missed it, the American Society on Aging held its annual conference last week in Chicago, IL, where Lori Reilly, PhRMA executive vice president of policy, research & membership, spoke...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates